Arix Bioscience co-leads $31 million Series A financing for new portfolio company Sorriso Pharmaceuticals
Arix Bioscience co-leads $31 million Series A financing for new portfolio companySorriso Pharmaceuticals Arix announces a new portfolio company, Sorriso, with a 26% ownership stakeSeries A proceeds will enable Sorriso Pharmaceuticals to advance its lead programme, a treatment for IBD, into clinical trialsArix M...